SecBot SecBot

CLDX

Celldex Therapeutics, Inc.
Nasdaq· In Vitro & In Vivo Diagnostic Substances· Inc. DE· CIK 0000744218 Biotech & Drug Discovery
$28.59 −0.24 (−0.83%)
Nov 16 4:00 PM ET · prev $28.83
Market cap
$2.2B
Mid cap
Consensus
Buy
90% Buy or better · 21 analysts
Median target
$66.00
+131% · range $29.00–100.00
1 year
+10.0%
from $26.00 · Nov 17
30 days
−3.6%
from $29.67
52-week range
$22.58–44.87
−36% from high · low Feb 5
Avg volume 20D
901.6K
shares / day
Short interest
9.94M
≈12.7% of shares · +3.5%
Days to cover
10.3
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
2
Q2 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 0 bearish · 3 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 32 added (2 new), 11 trimmed or exited. Largest new: Driehaus Capital Management $36.8M, Federated Hermes, $18.3M.

  • AnalystsBULLISH

    19 of 21 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.999 → −$1.004 over 90 days. 1 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.5% to 9.94M shares. 10.3 days to cover, ≈12.7% of shares.

  • TrendRANGE

    10% below its 50-day average.

Who's buying

13F· Q2 2026
2
new positions
0
exits
$55.2M
in new stakes
FundMoveSharesValue
BlackRock, Inc.ADD7,002,530$260.6M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED4,685,223$174.3M
STATE STREET CORPADD3,900,427$145.1M
GOLDMAN SACHS GROUP INCADD1,615,343$60.1M
BAKER BROS. ADVISORS LPADD1,182,611$44.0M
DRIEHAUS CAPITAL MANAGEMENT LLCNEW989,442$36.8M
VANGUARD PORTFOLIO MANAGEMENT LLCADD863,536$32.1M
Assenagon Asset Management S.A.DOUBLED788,696$29.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 90% rate it Buy or better
Strong Buy7Buy12Hold2Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +131%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Nov 9, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 2, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 23, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Sep 23, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Sep 22, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 25, 2026
PENNER HARRY JR
Director
Jun 25, 2026
AWARD26,000 sh
Jun 25, 2026
NEIL GARRY ARTHUR
Director
Jun 25, 2026
AWARD26,000 sh
Jun 25, 2026
Cohen Cheryl
Director
Jun 25, 2026
AWARD26,000 sh
Jun 25, 2026
Torres Denice
Director
Jun 25, 2026
AWARD26,000 sh
Jun 25, 2026
Brownlie Keith L
Director
Jun 25, 2026
AWARD26,000 sh
Jun 25, 2026
MARINO JAMES J
Director
Jun 25, 2026
AWARD26,000 sh
Jun 25, 2026
Jain Rita
Director
Jun 25, 2026
AWARD26,000 sh
Jun 25, 2026
Marucci Anthony S
PRESIDENT & CEO
Jun 25, 2026
AWARD375,000 sh

Earnings setup

Estimates
−$1.00
EPS estimate, this quarter
−0%
estimate change, 90 days
1↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.00-$1.07–-$0.88+0.6%$1.5M
Next Q-$0.97-$1.14–-$0.81-6.7%$250.0K
Current FY-$4.05-$4.27–-$3.65+1.9%$1.4M
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
9,936,646
shares short
+3.5%
vs prior settlement
10.3
days to cover
≈12.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 11, 2026 Earnings calendar
CLDX Q3 2026 Earnings Scheduled · 2026-11-11
Nov 5, 2026 SEC
Celldex filed an automatic shelf registration statement (S-3ASR) on November 5, 2026, registering an indeterminate…
S-3ASR · Impact 3/10
Nov 5, 2026 SEC
Celldex reported Q3 2026 results with no material revenue and a net loss of $75.6M ($0.96 per share), slightly better…
8-K · Impact 5/10
Sep 22, 2026 Press
Celldex reported positive Phase 3 topline results for barzolvolimab in chronic spontaneous urticaria (CSU). Both…
Impact 7/10
Jun 30, 2026 Inst.
BlackRock, Inc. · ADD
7,002,530 shares ($260.6M)
Jun 30, 2026 Inst.
PRICE T ROWE ASSOCIATES · DOUBLED
4,685,223 shares ($174.3M)
Jun 25, 2026 Insider
PENNER HARRY JR was granted 26,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 11, 2026
Earnings date
CLDX Q3 2026 Earnings Scheduled · 2026-11-11
Nov 4, 2026
Press release
Celldex to Present at Upcoming Investor Conferences
HAMPTON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at two…
Oct 12, 2026
Press release
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on…
Sep 30, 2026
Short interest
Short Interest: CLDX up 23% to 11.0M shares
Settlement 2026-09-30 | Days to cover: 3.81 | ≈14.02% of shares outstanding (est.)
Sep 22, 2026
FDA
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
HAMPTON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported positive topline results from the Company’s Phase 3…

SecBot reports

13 filings · 8 press releases · 3 bullish · 1 bearish · 2 mixed · 7 neutral
All CLDX filing & press-release reports (21)